Fei Tang
Overview
Explore the profile of Fei Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
380
Citations
3400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Zhang M, Tang F, Wang H, Gao J, Li M, et al.
Mycology
. 2025 Mar;
16(1):158-179.
PMID: 40083417
mushrooms are esteemed as a rare and highly valuable resource for both culinary and medicinal purposes. Ancient medical classics have documented their beneficial effects on conditions such as indigestion, loss...
2.
Zhao X, Xu L, Li K, Tang F, Liu D, Zhang J, et al.
J Ethnopharmacol
. 2025 Mar;
:119616.
PMID: 40074099
Ethnopharmacological Relevance: 5-Fluorouracil (5-FU) commonly induces severe mucositis, causing pain, inflammation, and gastrointestinal dysfunction, which significantly increases patient morbidity and reduces quality of life. In Ayurveda, Traditional Chinese Medicine, and...
3.
Zhang L, Zhao X, Cao Z, Li K, Xu L, Tang F, et al.
Phytomedicine
. 2025 Mar;
140:156516.
PMID: 40054176
Background: Gastric cancer remains a leading cause of cancer mortality, with oxaliplatin (L-OHP) resistance posing a major therapeutic challenge. Ginsenosides have shown potential in addressing chemoresistance. Purpose: This study aimed...
4.
Single-Cell/Particle Sample Introduction Device for Mass Cytometry Based on Gas-Driven Flow Focusing
Chen H, Liu J, Zhao Y, Xu H, Liu W, Xing Z, et al.
Anal Chem
. 2025 Feb;
97(8):4590-4597.
PMID: 39960459
Mass cytometry is considered the second generation of flow cytometry technology, which uses metal-labeled antibodies instead of traditional fluorescent antibodies and can measure much more markers from a single cell...
5.
Tawfik S, Tang F
J Clin Pharmacol
. 2025 Feb;
PMID: 39930960
Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease-specific factors. For mAbs in non-oncology...
6.
Li C, Zhou Y, Tang F
Opt Lett
. 2025 Jan;
50(3):766.
PMID: 39888748
This publisher's note contains a correction to Opt. Lett.49, 6928 (2024)10.1364/OL.544994.
7.
Yan F, Tang F, Chen J, Lin Y, Chen X, Du Q, et al.
Front Immunol
. 2025 Jan;
15:1528758.
PMID: 39867915
Objective: Although pegylated interferon α-2b (PEG-IFN α-2b) therapy for chronic hepatitis B has received increasing attention, determining the optimal treatment course remains challenging. This research aimed to develop an efficient...
8.
Wu Q, Wu H, Hu Y, Zheng X, Chang F, Liu Y, et al.
Antiviral Res
. 2025 Jan;
235:106092.
PMID: 39864525
The Omicron BA.2.86 subvariants, JN.1, KP.2, and KP.3, have become predominant globally, raising concerns about their immune evasion from vaccines and monoclonal antibody (mAb) treatments. These variants harbor more receptor-binding...
9.
Zhao X, Cao Z, Li K, Tang F, Xu L, Zhang J, et al.
Front Pharmacol
. 2025 Jan;
15():1515172.
PMID: 39840111
Atherosclerotic cardiovascular disease (ASCVD) causes significant morbidity and mortality globally. Most of the chemicals specifically target certain pathways and minimally impact other diseases associated with ASCVD. Moreover, interactions of these...
10.
Xiao J, An X, Tang F, Dai X, Zhang S, Zhu X, et al.
Adv Healthc Mater
. 2025 Jan;
e2404525.
PMID: 39831851
Bacterial infections can lead to severe medical complications, including major medical incidents and even death, posing a significant challenge in clinical trauma repair. Consequently, the development of new, efficient, and...